Fortis Healthcare files DRHP with SEBI to raise funds

In order to raise money in the primary markets, Agilus Diagnostics Limited, a subsidiary of Fortis Healthcare, has submitted its Draught Red Herring Prospectus (DRHP) to market regulator Securities and Exchange Board of India (SEBI).

International Finance Corporation I, NYLIM Jacob Ballas India Fund III LLC, and Resurgence PE Investments will be selling up to 14,233,964 equity shares in the offering for sale (OFS).

The OFS would see the sale of up to 29.85 lakh shares by International Finance Corporation and up to 74.62 lakh and 37.86 lakh equity shares by NYLIM Jacob and Resurgence, respectively.

The face value of the shares is Rs 10 each.

As of March 31, 2023 for the relevant fiscal year, the company, which is promoted by Fortis Healthcare, asserts to be India's largest diagnostics service provider in terms of laboratory count and second largest in terms of revenue from operations.

ICICI Securities Limited, Axis Capital Limited, and Citigroup Global Markets India Private Limited are the issue's book-running lead managers, and KFin Technologies Limited is the registrar.